Close

Dr Ed Clarke

Professor - Theme Leader

United Kingdom

Affiliations

MRC Unit The Gambia at LSHTM

Selected Publications

Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.
Zehrung, D; Innis, BL; Suwantika, AA; Ameri, M; Biellik, R; Birchall, JC; Cravioto, A; Jarrahian, C; Fairlie, L; Goodson, JL; Kochhar, S; Kretsinger, K; Morgan, C; Mvundura, M; Rathi, N; CLARKE, E; Mistilis, JJ; Uwamwezi, M-C; Giersing, B; Hasso-Agopsowicz, M;
2024
Vaccines
Collecting and reporting adverse events in low-income settings-perspectives from vaccine trials in the Gambia.
BRUCE, AA-A; Umesi, A-O; Bashorun, A; Ochoge, M; Yisa, M; Obayemi-Ajiboye, D; Futa, A; Njie, A; Asase, S; Jallow, MB; Kotei, L; Affleck, L; Olubiyi, OA; Jarju, LB; Kanyi, M; Danso, B; Zemsi, A; CLARKE, E;
2024
Trials
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme, I; Yisa, M; OOKO, M; Akpalu, E; Bruce, A; Donkor, S; Jarju, LB; Danso, B; Mendy, A; JEFFRIES, D; Segonds-Pichon, A; Njie, A; Crooke, S; El-Badry, E; Johnstone, H; Royals, M; Goodson, JL; Prausnitz, MR; McAllister, DV; Rota, PA; Henry, S; CLARKE, E;
2024
Lancet (London, England)
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Ochoge, M; Futa, AC; Umesi, A; Affleck, L; Kotei, L; Daffeh, B; Saidy-Jah, E; Njie, A; Oyadiran, O; Edem, B; Jallow, M; Jallow, E; Donkor, SA; Tritama, E; Abid, T; Jones, KA V; Mainou, BA; Konz, JO; Fix, A; Gast, C; CLARKE, E;
2024
Lancet (London, England)
Practical Guidelines for Standardised Resolution of Important Protocol Deviations in Clinical Trials Conducted in Sub-Saharan Africa.
Zemsi, A; Nekame, LJ G; MOHAMMED, N; Batchilly, ES; Dabira, E; Sillah, SO; Sey, G; Williams, DH; Dondeh, B-L; CERAMI, C; CLARKE, E; D'ALESSANDRO, U;
2024
Therapeutic innovation & regulatory science
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study.
Bashorun, AO; Kotei, L; Jawla, O; Jallow, AF; Saidy, AJ; Kinteh, M-A; Kujabi, A; Jobarteh, T; Kanu, FJ; Donkor, SA; Ezeani, E; Fofana, S; Njie, M; Ceesay, L; Jafri, B; Williams, A; JEFFRIES, D; KOTANMI, B; Mainou, BA; OOKO, M; CLARKE, E;
2024
The Lancet. Infectious diseases
Meningococcal Vaccine in Mali and Gambia. Reply.
CLARKE, E; Alderson, MR; Tapia, MD;
2023
The New England journal of medicine
Prevalence of five treatable sexually transmitted infections among women in Lower River region of The Gambia.
BUTCHER, R; JARJU, S; Obayemi, D; BASHORUN, AO; VASILEVA, H; Bransbury-Hare, H; Agboghoroma, O; Drammeh, L; HOLLAND, M; HARDING-ESCH, E; CLARKE, E;
2023
BMC infectious diseases
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.
Haidara, FC; Umesi, A; Sow, SO; Ochoge, M; Diallo, F; IMAM, A; Traore, Y; Affleck, L; Doumbia, MF; Daffeh, B; Kodio, M; WARIRI, O; Traoré, A; Jallow, E; KAMPMANN, B; Kapse, D; Kulkarni, PS; Mallya, A; Goel, S; Sharma, P; Sarma, AD; Avalaskar, N; LaForce, FM; Alderson, MR; Naficy, A; ... CLARKE, E.
2023
The New England journal of medicine
See more information